Brink Biologics

Brink Biologics leverages the NK-92 cell line to create standardized bioassays for the biopharmaceutical industry, offering a suite of engineered NK cell lines (aNK, haNK, taNK, etc.) under a licensing model. Its core business is providing 'killer assays' as tools for target validation, drug screening, potency testing, and immunogenicity assessment, primarily serving commercial and academic research clients. As an affiliate of the publicly traded ImmunityBio, it occupies a specialized niche in the contract research and development tools landscape, enabling more predictive and uniform cell-based testing for oncology and immunology therapeutics.

Proprietary panel of engineered NK-92 cell lines (Neukopanel®) including activated (aNK), antibody-dependent (haNK/laNK), and CAR-equipped (taNK) variants, used as standardized effector cells for bioanalytical testing.

Brink competes with large contract research organizations (CROs) offering cell-based assay services, reagent companies selling primary immune cells or engineered cell lines, and the in-house assay development capabilities of large biopharma. Its differentiation lies in its exclusive focus on a standardized, deeply engineered NK-92 platform, offering consistency and expertise in 'killer assays' that may be fragmented across other providers.